KLRK1 and neoplasm: Here, we demonstrated that the combination of a dual inhibitor, AT-0174, plus PD-1 blockade markedly enhanced NKG2D frequency on NK and CD8+ T cells which led to a reduction in tumor growth and tumor weight compared to monotherapy, and prolonged survival.